$300 Million

argenx SE

Follow-on Offering

Bookrunner, September 2018

argenx SE
argenx SE is a clinical-stage biotechnology company developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Utilizing its suite of differentiated technologies, the Company is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. argenx’s SIMPLE Antibody Platform, based on the powerful llama immune system, allows the Company to exploit novel and complex targets, and its three Fc engineering technologies are designed to enable argenx to expand the therapeutic index of its product candidates. argenx’s most advanced product candidate, ARGX-113, recently entered a Phase 3 registrational trial in Q3 2018 for the treatment of the rare autoimmune disease, myasthenia gravis, or MG. ARGX-113 is also being developed in two other indications: immune thrombocytopenia (ITP) and pemphigus vulgaris (PV).